Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Palo Alto Networks Inc (PANW) vs Sana Biotechnology Inc (SANA) Price & Performance

Palo Alto Networks IncTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Palo Alto Networks Inc vs Sana Biotechnology Inc — how do they compare? Palo Alto Networks Inc trades at $336.35 (market cap $274.64B), while Sana Biotechnology Inc trades at $3.17 (market cap $1.03B). The key difference: Palo Alto Networks Inc is far larger — about 266.6× Sana Biotechnology Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.

PANWSANA
Market Cap
$274.64B$1.03B
Sector
TechnologyHealth
52-Week High
$396.00$5.92
52-Week Low
$141.67$2.68
Enterprise Value
$273.60B$946.04M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Palo Alto Networks Inc

Palo Alto Networks (PANW) trades at $336.98, up 1.12% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $9.22B in FY2025, with strong gross margins of 71.94%, but valuation ratios are elevated (P/E 293.03, P/S 23.39). The company is set to join the S&P 500, reflecting its leadership in AI cybersecurity, though rising costs and premium pricing pose challenges.

Outlook remains positive due to AI-driven security demand and platformization strategy, but high valuation and competitive pressures warrant caution. Analyst consensus is bullish with a $410.48 price target, yet near-term volatility may persist as the stock digests recent gains and faces execution risks in a dynamic cybersecurity landscape.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.

Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Palo Alto Networks Inc

Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.

Read more on PANW

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA